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Abstract
Introduction: Genetic variability related to the host immune system has been proposed as one of the 
most influential factors in the development of diseases caused by HPV. Clinical case: We report the 
case of a 5-year-old child in whom chronic laryngeal papillomatosis, probably acquired vertically du-
ring labor, was detected. The diagnosis of laryngeal papillomatosis was confirmed with a biopsy after 
a first surgery to remove the papillomas. The Derkay classification system was used to assess the se-
verity of papillomatosis. Biopsy genotyping was performed by demonstrating HPV-6. Later, HLAD-
QA1*0505, -DQB1*0301, -DRB1*1101 alleles were homozygous for HLA allele typing. Conclusions: 
Further studies are needed to identify the most prevalent HLA alleles in the Latino population and 
their potential association with genetic susceptibility in Recurrent Respiratory Papillomatosis.
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Introduction
The only known disease secondary to perinatal 
transmission of human papillomavirus (HPV) type 6 
or 11 (HPV-6, HPV-11) is recurrent respiratory papi-
llomatosis (RRP)1. When symptoms begin to manifest 
before 5 years old, RRP is generally classified as “juve-
nile onset” (juvenile-onset; JO-RRP).
The earlier the onsets age of the symptoms, the 
more severe the disease2,3. The incidence of RRP in 
children varies between 1.7-4.3/100,000, with no signi-
ficant differences when separated by race or gender2,4.
There are different risk factors involved in the de-
velopment of HPV pathology. The genetic variability 
related to the host immune system has been proposed 
as one of the most influential, since it could play an 
important role in the defensive response against the vi-
rus5,6. Evidence indicates that cellular immunity would 
be compromised in children with RRP. Patients with a 
more aggressive clinical course may have an immuno-
deficiency associated with this immunity7. However, it 
is still unclear whether HPV causes this alteration in 
immunity or if children with impaired immunity deve-
lop RRP. As well as the susceptibility to cervical cancer 
caused by HPV has been related to some specific HLA 
alleles, similarly it has been seen that this association 
is fulfilled in patients with RRP, where certain alleles 
influence the course of the disease, favoring the severi-
ty8-10 or, on the contrary, fulfilling a protective role11,12.
Clinical case
A 5-year-old male with prolonged dysphonia (since 
he was 8 months of age, according to his mother) and 
a clinical diagnosis of laryngeal papillomatosis. He was 
admitted to the Otorhinolaryngology Service (ORLS) 
of the Dr. Hernán Henríquez Aravena Hospital in Te-
muco, Chile. A gynecological check during pregnancy 
of the child’s mother described vaginal condylomas. 
However, such lesions were not considered contrain-
dications to vaginal delivery. Although the mother did 
not receive treatment, the condylomas were not descri-
bed during labor. Once the patient was admitted to the 
ORLS, a direct laryngoscopy showed papillomatous 
lesions in the vocal cords, confirming the diagnosis 
of laryngeal papillomatosis with a biopsy after a first 
surgery to remove the papillomas. The Derkay Score 
system was used to evaluate the severity of papilloma-
tosis13, which indicated a score of 21, which coincided 
with a moderate clinical picture. Because papilloma-
tous lesions and dysphonia were recurrent, the child 
underwent five surgical interventions in total, all of 
them for therapeutic purposes and always obtaining a 
sample for biopsy. No adjuvant therapy was conside-
red. The strategy consisted on operating a vocal cord 
first and three or four months later the contralateral 
vocal cord, in order to avoid synechia between two 
bloody surfaces.
Surgeries were performed when the patient was 5 
years old and 8 months; 7 years and 2 months; 7 years 
and 5 months; 8 years and 7 months, and finally 8 years 
and 11 months of age.
After the second surgery, genotyping was reques-
ted for HPV. Using a commercial kit (HPV type 3.5 
LCD-Array Kit, Chipron GmbH, Berlin, Germany) 
and following the manufacturer’s instructions, HPV-
6 was detected in the patient’s laryngeal tissue sample 
(figure 1).
Immunological exams indicated that levels of ce-
llular immunity markers were normal (BD FacScan, 
San Jose, CA, USA). Only a slight elevation in serum 
IgM was found. The level of the other immunoglo-
bulins and complement components were not altered 
(BN ProSpec System, Siemens, Health Care Diagnos-
tics, Inc.). Primary immunodeficiency or HIV, HCV or 
HBV infection (Architect i8200, Abbott, Abbott Park, 
IL, USA) were ruled out (table 1).
For the typing of HLA alleles of the patient, com-
mercial kits were used according to the manufacturer’s 
instructions (Micro SSPTM Allele Specific HLA Class 
II DNA Typing Tray) (HLA Celiac, Inc. 21001 Kittrid-
ge Street, Canoga Park, CA) Disease [PROTRANS me-
dizinische diagnostische Produkte GmbH, Hockenhe-
im, Germany]). The results are summarized in table 2.
Currently, the patient is 11 years and 9 months old, 
is healthy and has a very good quality of life, he norma-
lly attends classes and he is being clinically controlled 
regularly.
Discussion
To date, no results of a HLA class II allele typing 
have been published in Chilean children with RRP. 
However, studies in other populations, mainly Cau-
casian, describe associations between HLA alleles and 
susceptibility to RRP.
The HLA analysis in our patient shows a homo-
zygous state for alleles DQA1*0505, DQB1 *0301 
and DRB1*1101. The haplotypes DRB1*1101 and 
DRB1*1101 DQB1*0301 have been strongly associa-
ted with susceptibility to severe RRP in Korean pa-
tients14, although a study with patients with JO-RRP 
and RRP “adult-onset; AO-RRP), mainly Caucasians 
and to a lesser percentage of African-Americans and 
Hispanics, revealed that there would be no increase 
in the prevalence of DQB1*0301 or association of the 
allele with the severity of the disease15, which would 
agree more with our patient showing a moderate cli-
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Table 1. Cell immunity and serological markers
test Results Range Method
total leukocytes 8780 x mm3 5.000 - 15000 x mm3 -
CD19 (B cells) 323 x mm3 200 - 600 x mm3
Flow Cytometry
CD3 (t cells) 1956 x mm3 700 - 3500 x mm3
CD4 (helper t cells) 935 x mm3 300 - 2100 x mm3
CD8 (cytotoxic t cells) 925 x mm3 300 - 1200 x mm3
CD4/CD8 ratio 1.01 0.90 - 3.40 -
CD16+56 401 x mm3 90 - 1200 x mm3 Flow Cytometry
C3 122 mg/dl 80 - 170 mg/dl
nephelometry
C4 19 mg/dl 14 - 44 mg/dl 
IgG 1334 mg/dl 540 - 1822 mg/dl
IgA 211 mg/dl 21 - 291 mg/dl
IgM 221 mg/dl 41 - 183 mg/dl
total IgE 70 UI/ml < 90 UI/ml
Surface antigen of the Hepatitis B virus 
(HBsAg)
0.16 < 2.0 (negative)
≥ 2.0 (Positive)
ChemiluminescenceHepatitis C virus (anti-HCV) 0.12 < 1.0 (non-reactive)
≥ 1.0 (Reactive)
HIV Ag p24, anti-HIV negative -
Figure 1. Results of hybridisation with DNA from the patient's laryngeal tissue and specific probes for 32 HPV serotypes on a commercial 
matrix (HPV type 3.5 LCD-Array Kit). Positive result for HPV-6.
Table 2. Typing of HLA class II alleles
HlA allele Absent Heterozygote Homozygote
DQA1*0505 - - X
DQB1*0301 - - X
DRB1*1101 - - X
nical picture, and a Derkay score of 21. Up to now the 
DQA1*0505 allele has not been associated with RRP 
susceptibility or HPV infection, however, interestin-
gly, the DRB1*11-DQA1*0505 alleles have been as-
sociated with Variable immunodeficiency in Iranian 
patients16. However, in our case, a known primary im-
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munodeficiency and an immunodeficiency secondary 
to HIV were ruled out.
To date, published information concerning HLA 
genes and their possible association with RRP sus-
ceptibility refers primarily to alleles other than those 
published in this case. HLA-DRB1*14 has been asso-
ciated with susceptibility to JO-RRP, whereas HLA-
DRB1*0301 with susceptibility to AO-RRP. Interestin-
gly, patients homozygous for HLA-DRB1*0301 show a 
more severe clinical picture8.
Also, it has been shown that the HLA-DQA and 
HLA-DQB1 alleles present in different proportions in 
children with RRP regarding their controls. In addi-
tion to influencing the risk of RRP, the frequencies of 
alleles and haplotypes mentioned have some influence 
on the course of the disease, regardless of the HPV ge-
notype involved10.
In 2004 it was suggested for the first time that a 
high frequency of HLA- DRB1*0102 was associated 
with predisposition to RRP in Caucasian individuals. 
The HLA-DRB1*0301, DQB1*0201 and DQB1*0202 
alleles showed increased frequency in Caucasians with 
severe disease, indicating that such alleles could be 
involved in regulating the severity of the disease. In-
terestingly, HLA-DRB1*0301 and DQB1*0201 were 
associated with reduced interferon-gamma (IFN-γ) 
expression. On the other hand, the HLA-DQB1*0602 
allele was more frequent in controls than in Cauca-
sians with severe disease, suggesting a control effect of 
the severity by that allele. While DQB1*0602 was ab-
sent, the DQB1*0201 and DQB1*0202 alleles showed 
increased frequency in African Americans9. More re-
cently, only results indicating a potential protective 
role for DQB1*0602 could be replicated by Rodier C. et 
al. (eleven). Similarly, another study shows that about 
80% of patients with severe RRP lack this protective 
allele12. An important ethnic difference has to do with 
the HLA-DQA*0102 allele, whose presence is associa-
ted with a high risk of developing RRP in Caucasian 
patients but with remission of the disease in African 
American patients10.
From the HLA typing of our patient it is inferred 
that the HLA-DQA*0102, DQB1*0201, DQB1*0202, 
DQB1*0602, DRB1*0102, DRB1*0301 and DRB1*14 
alleles are not present.
To date, studies reported on HLA genes and sus-
ceptibility to RRP mainly involve work with Cauca-
sian patients, with some ethnic variability in the re-
sults. We believe that future studies in Latin popu-
lations are necessary to determine the prevalence of 
HLA alleles, their potential association with genetic 
susceptibility to RRP, the severity of the clinical pic-
ture and the influence on the course of the disease in 
these patients. Similarly, it is important to determine 
a link between these alleles and some known or unk-
nown primary immunodeficiency, which could be a 
prior history that facilitates HPV infection or a con-
sequence thereof.
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